These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 11367483)

  • 1. A chat with HIV specialists: the Geneva report.
    Newsline People AIDS Coalit N Y; 1998 Sep; ():12-7. PubMed ID: 11367483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term strategies: should some patients wait to start protease inhibitors? Interview with Keith Henry, M.D. Interview by John S. James.
    Henry K
    AIDS Treat News; 1997 Oct; (No 281):1, 3-6. PubMed ID: 11364791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experts clarify issues raised by combination therapy.
    AIDS Alert; 1998 May; 13(5):suppl 1-2. PubMed ID: 11365415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Body changes and blood abnormalities: the lipodystrophy and fat redistribution conundrum.
    Martinez LJ
    Res Initiat Treat Action; 1999 Apr; 5(2):22-5. PubMed ID: 11366281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AIDS practice issues today: interview with Paul Bellman, M.D. Interview by John S. James.
    Bellman P
    AIDS Treat News; 2000 Apr; (No 340):1-6. PubMed ID: 11367198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicians explore ways to ensure compliance.
    AIDS Alert; 1997 Feb; 12(2):17-8. PubMed ID: 11364031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipodystrophy studies in women.
    Proj Inf Perspect; 1999 Apr; (27):16. PubMed ID: 11366732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up.
    Negredo E; Paredes R; Bonjoch A; Tuldrà A; Fumaz CR; Gel S; Garcés B; Johnston S; Arnó A; Balagué M; Jou A; Tural C; Sirera G; Romeu J; Cruz L; Francia E; Domingo P; Arrizabalaga J; Ruiz I; Arribas JR; Ruiz L; Clotet B
    Antivir Ther; 1999; 4 Suppl 3():23-8. PubMed ID: 16021868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Switch strategy: replacing the protease inhibitor. Quality of life improves].
    MMW Fortschr Med; 2000; 142(3 Suppl):37. PubMed ID: 11012292
    [No Abstract]   [Full Text] [Related]  

  • 10. Lipodystrophy.
    Proj Inf Perspect; 1999 Apr; (27):14-5. PubMed ID: 11366731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HAL in 2001: a fat oddity.
    Grinberg L; Torres G
    GMHC Treat Issues; 1999 Mar; 13(3):2-5, 8. PubMed ID: 11366203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double jeopardy: the hazards of drug-drug interactions.
    Flexner C
    Res Initiat Treat Action; 1998 Dec; 4(7):3-8. PubMed ID: 11366084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are changes in body shape due to drug side effects?
    TreatmentUpdate; 1999 Jun; 11(4):3-4. PubMed ID: 11366790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient adherence, not viral load now most important in HIV therapy.
    Rep Med Guidel Outcomes Res; 2000 Feb; 11(3):6-7. PubMed ID: 11768406
    [No Abstract]   [Full Text] [Related]  

  • 15. Wasting and body changes: what do we know so far?
    Gomez E
    Newsline People AIDS Coalit N Y; 1998 Sep; ():34-6. PubMed ID: 11367489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence and double therapies: an interview with Charles Farthing, M.D. Interview by Marcelo Marer.
    Farthing C
    Body Posit; 1998; 11(4-5):28-33. PubMed ID: 11365254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of discontinuing stavudine or protease inhibitor therapy on human immunodeficiency virus-related fat redistribution evaluated by dual-energy x-ray absorptiometry.
    Tavassoli N; Bagheri H; Sommet A; Delpierre C; Marion-Latard F; Massip P; Aquilina C; Bonnet E; Obadia M; Labau E; Montastruc JL; Bernard J
    Pharmacotherapy; 2006 Feb; 26(2):154-61. PubMed ID: 16466321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. STEP's 12th World AIDS Conference report.
    Schouten JT
    STEP Perspect; 1998; 98(3):8-12. PubMed ID: 11365829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence over 48 weeks in an antiretroviral clinical trial: variable within patients, affected by toxicities and independently predictive of virological response.
    Nieuwkerk P; Gisolf E; Sprangers M; Danner S;
    Antivir Ther; 2001 Jun; 6(2):97-103. PubMed ID: 11491422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Popping pills for life.
    Focus; 1998 Feb; 13(3):5-6. PubMed ID: 11365169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.